Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share (the "Shares")
-
Shares outstanding
-
31,306,673
-
Total 13F shares
-
14,483,960
-
Share change
-
+14,441,516
-
Total reported value
-
$165,920,957
-
Price per share
-
$11.52
-
Number of holders
-
17
-
Value change
-
+$165,375,910
-
Number of buys
-
16
Institutional Holders of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV) as of Q4 2022
As of 31 Dec 2022,
Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV) was held by
17 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
14,483,960 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., PERCEPTIVE ADVISORS LLC, Sands Capital Ventures, LLC, CITADEL ADVISORS LLC, MARSHALL WACE, LLP, WELLINGTON MANAGEMENT GROUP LLP, FEDERATED HERMES, INC., HealthCor Management, L.P., BANK OF MONTREAL /CAN/, and GOLDMAN SACHS GROUP INC.
This page lists
17
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.